JBIO Key Statistics, Chart & Performance
The current stock price of JBIO is 16.45 USD. In the past month the price increased by 31.81%.
JBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About JBIO
Company Profile
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2021-06-30. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Company Info
JADE BIOSCIENCES INC
221 Crescent St., Building 23, Suite 105
Waltham MASSACHUSETTS US
Employees: 4
Phone: 17813123013
JADE BIOSCIENCES INC / JBIO FAQ
What does JBIO do?
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2021-06-30. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Can you provide the latest stock price for JADE BIOSCIENCES INC?
The current stock price of JBIO is 16.45 USD. The price decreased by -0.48% in the last trading session.
What is the dividend status of JADE BIOSCIENCES INC?
JADE BIOSCIENCES INC (JBIO) has a dividend yield of 510.64%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of JBIO stock?
JBIO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of JADE BIOSCIENCES INC (JBIO)?
JADE BIOSCIENCES INC (JBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.14).
What is JADE BIOSCIENCES INC worth?
JADE BIOSCIENCES INC (JBIO) has a market capitalization of 756.70M USD. This makes JBIO a Small Cap stock.
What is the next earnings date for JBIO stock?
JADE BIOSCIENCES INC (JBIO) will report earnings on 2026-03-23, after the market close.
JBIO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to JBIO.
JBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to JBIO. No worries on liquidiy or solvency for JBIO as it has an excellent financial health rating, but there are worries on the profitability.
JBIO Financial Highlights
Over the last trailing twelve months JBIO reported a non-GAAP Earnings per Share(EPS) of -11.14. The EPS increased by 89.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.23% | ||
| ROE | -36.39% | ||
| Debt/Equity | 0 |
JBIO Forecast & Estimates
13 analysts have analysed JBIO and the average price target is 21.08 USD. This implies a price increase of 28.15% is expected in the next year compared to the current price of 16.45.